The global macular degeneration treatment market size reached USD 9.9 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 15.8 Billion by 2033, exhibiting a growth rate (CAGR) of 5.28% during 2025-2033. The market is majorly driven by the increasing incidences of age-related macular degeneration and obesity among the masses, growing prevalence of sedentary lifestyles, rapid utilization of smart devices, and significant improvements in the healthcare infrastructure, particularly in developing economies.
Macular degeneration is a neurodegenerative ocular disorder that affects the eyes and causes blurred or loss of vision in the center of the visual field. It is characterized by blind spots in the field of vision, visual distortions and inability to see in low light conditions. Some of the commonly used therapeutic techniques for macular degeneration includes anti-angiogenic drugs, photodynamic laser therapies, contact lenses and transitional lenses. Laser therapy involves the insertion of specialized contact lenses into the affected are of the eye, which are sealed by lasers along with the blood vessels. Anti-angiogenic drugs are used for preventing blockages and leakages in the blood vessels. Timely treatment of macular degeneration treatment can aid in enhancing vision and minimizing the risks of developing chronic blindness.
Macular Degeneration Treatment Market Trends:
The increasing incidences of age-related macular degeneration and obesity among the masses is one of the key factors driving the market growth. The changing dietary patterns and the rising adoption of sedentary lifestyles is leading to the development of macular degeneration. Additionally, the increasing utilization of smartphones, laptops and television, which is leading to prolonged and excessive screen time is also impacting the occurrence of the disorder. Moreover, the development of retinal gene therapies that involves the injection of adeno-associated virus (AAV) into the body for preventing the development of abnormal blood vessels is providing a thrust to the market growth. In line with this, significant improvements in the healthcare infrastructure is positively impacting the market growth. Other factors, including extensive research and development (R&D) activities for the development of innovative and effective drugs, along with the implementation of various government initiatives for promoting public health, are anticipated to drive the market toward growth.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2025-2033. Our report has categorized the market based on type, stage of disease, route of administration, and end user.
Breakup by Type:
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Early Stage
- Intermediate Stage
- Late Stage
- Intravenous Route
- Intravitreal Route
- Hospitals
- Ambulatory Surgical Center
- Others
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd.
Key Questions Answered in This Report
1.What was the size of the global macular degeneration treatment market in 2024?
2.What is the expected growth rate of the global macular degeneration treatment market during 2025-2033?
3.What are the key factors driving the global macular degeneration treatment market?
4.What has been the impact of COVID-19 on the global macular degeneration treatment market?
5.What is the breakup of the global macular degeneration treatment market based on the type?
6.What is the breakup of the global macular degeneration treatment market based on the stage of disease?
7.What is the breakup of the global macular degeneration treatment market based on the route of administration?
8.What is the breakup of the global macular degeneration treatment market based on the end user?
9.What are the key regions in the global macular degeneration treatment market?
10.Who are the key players/companies in the global macular degeneration treatment market?
- 1 Preface
- 2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
- 3 Executive Summary
- 4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
- 5 Global Macular Degeneration Treatment Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
- 6 Market Breakup by Type
- 6.1 Dry Age-related Macular Degeneration
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Wet Age-related Macular Degeneration
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 7 Market Breakup by Stage of Disease
- 7.1 Early Stage
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Intermediate Stage
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Late Stage
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 8 Market Breakup by Route of Administration
- 8.1 Intravenous Route
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Intravitreal Route
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
- 9 Market Breakup by End User
- 9.1 Hospitals
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Ambulatory Surgical Center
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Others
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
- 10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
- 11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
- 12 Value Chain Analysis
- 13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
- 14 Price Analysis
- 15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Aerie Pharmaceuticals Inc.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.1.3 Financials
- 15.3.2 Bausch Health Companies Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Bayer AG
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 F. Hoffmann-La Roche Ltd
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.5 Iveric Bio Inc.
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.6 Novartis AG
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Panoptica
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.8 Pfizer Inc.
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 Phio Pharmaceuticals
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.10 Regeneron Pharmaceuticals Inc.
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Regenxbio Inc.
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 Santen Pharmaceutical Co. Ltd.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook